EX-5.1 4 tm2630144d1_ex5-1.htm EXHIBIT 5.1

 

Exhibit 5.1

 

 

 

November 20, 2026

 

CytoSorbents Corporation

305 College Road East

Princeton, NJ 08540

 

Re: CytoSorbents Corporation, Registration Statement on Form S-3 (File No. 333-281062)

 

 Ladies and Gentlemen:

 

We have acted as counsel for CytoSorbents Corporation, a Delaware corporation (the “Company”), in connection with the offering and sale by the Company of (i) an aggregate of 556,681 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and 96,527 shares of Common Stock to the Company’s directors and certain executive officers (the “Common Shares”), (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 151,822 shares of Common Stock (the “Pre-Funded Warrant Shares”) pursuant to those certain Securities Purchase Agreements, each dated November 19, 2026, between the Company and with certain institutional and accredited investors named therein (the “Purchase Agreements”), and (iii) the issuance by the Company to Avenue Venture Opportunities Fund, L.P. (“Avenue”) of 202,429 shares of Common Stock (the “Registered Shares”) in satisfaction of $1,000,000 of outstanding indebtedness pursuant to the Third Amendment to Loan Documents, dated November 19, 2026 (the “Avenue Amendment”).

 

In connection with this opinion letter, we have examined the Company’s registration statement on Form S-3, as amended (Reg. No. 333-281062) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), which was declared effective on September 30, 2024, the prospectus supplement dated November 19, 2026 (the “Prospectus Supplement”) and the accompanying base prospectus dated September 30, 2024 (the “Base Prospectus”, and as supplemented by the Prospectus Supplement, the “Prospectus”) and originals, or copies certified or otherwise identified to our satisfaction, of the Second Amended and Restated Certificate of Incorporation, as amended, the Second Amended and Restated Bylaws of the Company, each of the Purchase Agreements, the Avenue Amendment and such other authorities, documents, records and other instruments as we have deemed appropriate for purposes of the opinions set forth herein.

 

We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents submitted to us as copies.

 

  Morgan, Lewis & Bockius LLP
     
  502 Carnegie Center
Princeton, NJ 08540-6241
+1.609.919.6600
     
  United States +1.609.919.6701

 

 

 

 

Based upon the foregoing, we are of the opinion that (i) the Common Shares, when issued and sold by the Company and delivered by the Company against receipt of the purchase price therefor, in the manner contemplated by the Prospectus and the Purchase Agreements will be validly issued, fully paid and non-assessable; (ii) when the Pre-Funded Warrant are issued, sold and delivered in the manner and for the consideration stated in the Registration Statement and the Prospectus, such Pre-Funded Warrant will be valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equity principles; (iii)  the Pre-Funded Warrant Shares, when issued and delivered by the Company upon exercise and payment of the exercise price of the Pre-Funded Warrants, in accordance with the terms thereof, will be validly issued, fully paid and non-assessable; and (iv) the Registered Shares, when issued and delivered by the Company to Avenue in satisfaction of $1,000,000 of outstanding indebtedness in accordance with the Avenue Amendment and in the manner contemplated by the Prospectus, will be validly issued, fully paid and non-assessable.

 

The opinions expressed herein are limited solely to the Delaware General Corporation Law without regard to choice of law, to the extent that the same may apply to or govern the transactions contemplated by the Registration Statement. We express no opinion as to the effect of events occurring, circumstances arising, or changes of law becoming effective or occurring, after the date hereof on the matters addressed in this opinion.

 

We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption “Legal Matters” in the Prospectus Supplement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the Commission thereunder.

 

Very truly yours,

 

/s/ Morgan, Lewis & Bockius LLP